31 results about "False-positive result" patented technology

The invention discloses a dry-type electrochemical luminescence (ECL) lateral flow chip and application thereof in CRISPR-Cas detection. The dry-type ECL lateral flow chip comprises a lateral flow test strip and an electrode plate, the lateral flow test strip comprises more than one detection test strip, one electric connection test strip and at least one quality control test strip; the test strip sequentially comprises an activation sheet, a combination sheet, a detection sheet, an absorption sheet and a common sample sheet, the test strip forms radial branches taking the sample piece as the center; the electrode plate comprises an integrated closed bipolar electrode and a driving electrode; the shape of the integrated closed bipolar electrode is the same as that of the lateral flow test strip. According to the invention, the CRISPR-Cas system is freeze-dried on the test strip, so that accurate multiple detection of pathogens can be realized; according to the method, the operation process is simplified, the detection time is greatly shortened, the operation error is reduced, the mutual interference among multiple detections is reduced, and the generation of false positive results is avoided.

This invention belongs to the field of agricultural and aquatic organism detection technology, specifically relating to a fluorescent RPA detection kit and its application method for detecting Ichthyophthirius multifiliis. Compared to traditional PCR technology, the detection kit and method of this invention significantly simplify the operation steps. Furthermore, after RPA amplification, the results can be directly interpreted through real-time fluorescence signals, eliminating the need for subsequent analysis operations such as opening the lid or electrophoresis. This avoids cross-contamination between different amplification products and reduces false positive results, greatly improving detection efficiency and accuracy. In aquaculture, this innovative RPA kit will significantly enhance the rapid on-site detection capability of Ichthyophthirius multifiliis, providing an efficient, simple, low-cost solution that does not require cold chain transportation, meeting the urgent need of modern aquaculture for rapid and accurate pathogen detection.

The invention relates to application of a Fe < 3 + >-ATP-CK cascade regulation type carbon dot fluorescent probe in dynamic monitoring of creatine kinase content, and relates to the field of new application of carbon dots. Fluorescence of B, N-CDs is quenched by Fe < 3 + >, and then fluorescence is recovered after ATP is added through specific binding of Fe < 3 + > and ATP. When CK catalyzes ATP to react with Cr, fluorescence is quenched again due to reduction of the ATP content. On the basis of high-selectivity competitive combination of Fe < 3 + > and ATP, interference of ADP, AMP and other analogues can be eliminated. The multiple verification mechanisms of Fe < 3 + > quenching, ATP recovery and CK re-quenching significantly reduce the false positive result, and enhance the detection reliability. A portable sensing platform constructed based on a smart phone establishes a new method for bedside detection of CK, establishes a brand new strategy for CK detection, and shows a wide prospect in rapid screening application of clinical diagnosis of myocardial infarction and the like.

The utility model relates to the technical field of gene detection, in particular to an EGFR (epidermal growth factor receptor) gene mutation multiple detection kit which comprises a kit body and a kit cover connected to the kit body, a fixing plate is fixedly arranged in the kit body, a plurality of first placing holes and a second placing hole are formed in the fixing plate, sponge rings are fixedly arranged in the first placing holes, and the sponge rings are fixedly arranged in the second placing holes. A reagent tube filled with a fluorescence labeling probe is arranged in the sponge ring, a sample tube is arranged in the second placing hole, and a sample dripping mechanism for adding a sample into the reagent tube in a dripping manner is further arranged on the fixing plate in a sliding manner; the sample dripping mechanism comprises a sliding block arranged on the fixing plate in a sliding manner, a fixing frame is fixedly arranged on the side wall of the sliding block, and a sample dripping hopper is fixedly arranged at the top of the fixing frame; according to the EGFR gene mutation multiple detection kit, a sample can be controlled to be dripped into the reagent tube in a dripping manner, so that the pouring amount of the sample is accurately controlled, and false negative or false positive results caused by non-uniform pouring of the sample are avoided.

The invention discloses a preparation method of a monoclonal antibody for detecting trichophyton rubrum and application of the monoclonal antibody in fungal skin disease detection, and belongs to the field of biological medicine. The monoclonal antibody provided by the invention only has specific reaction with trichophyton rubrum, and has no cross reaction with common fungi such as trichophyton mentagrophytes, epidermophyton flocculent, candida albicans, malassezia and the like and normal flora of a human body, so that a false positive result is effectively avoided. Based on the double-antibody sandwich principle, the detection sensitivity can reach 200 pg / mL level, trace trichophyton rubrum in a clinical sample can be detected, and the positive rate is obviously higher than that of direct microscopic examination. The whole detection process can be completed within 15-20 min and is far faster than fungus culture for several weeks, a rapid diagnosis basis can be provided for doctors, and early treatment is facilitated. The kit provided by the invention has standardized operation steps, does not need complex instruments and special training, and is suitable for popularization and use in clinical laboratories of hospitals at all levels, outpatient clinics of dermatology and even basic medical institutions.

The application discloses a biomarker for prognosis evaluation of extrahepatic cholangiocarcinoma, a prognosis risk evaluation system and application, and belongs to the technical field of bioinformatics. The application adopts the combination of miR-34c-5p, miR-100-5p, miR-193b-5p, miR-122-5p, miR-5588-5p and miR-122-3p as a biomarker, can effectively improve the accuracy of differential diagnosis of extrahepatic cholangiocarcinoma, can distinguish extrahepatic cholangiocarcinoma patients from healthy people and benign biliary disease patients with high precision, and overcomes the limitation that traditional tumor markers such as CA19-9 are prone to false positive results in benign biliary diseases. Meanwhile, the expression level change of the biomarker combination can dynamically reflect the postoperative tumor load change, and is helpful for accurately evaluating the surgical effect.

The invention discloses a primer pair, a kit and a system for detecting echinococcosis multilocularis based on multiple PCR-CRISPR / Cas12a of circulating free DNA (deoxyribonucleic acid), and application of the primer pair, the kit and the system, and relates to the technical field of gene detection. According to the primer pair for detecting the echinococcosis multilocularis based on the multiple PCR-CRISPR / Cas12a of the circulating free DNA, the 1260 gene, the Nad5 gene and the U1 gene of the echinococcosis multilocularis serve as targets, and the PCR primer pair comprises Em-1260-F4R3, Em-NAD5-F3R5 and Em-U1-F4R1. According to the invention, rapid and sensitive detection can be realized through a multiple PCR-CRISPR / Cas12a detection system, complicated equipment and operation are not needed, and the occurrence rate of false positive results is also reduced.

The invention discloses a reusable dual-mode aptamer biosensor for detecting clostridium perfringens, which is characterized by comprising a competitive chain CP-C, a CeO2 (at) PANI nano composite material, a closed bipolar electrode system and an aptamer functionalized magnetic bead probe. According to the invention, the high-affinity nucleic acid aptamer is combined with the specific extracellular electron transfer mechanism of the clostridium perfringens viable bacteria for the first time, a new viable bacteria detection sensing strategy free of nucleic acid extraction and target gene amplification is constructed, and the biosensor can specifically recognize the viable clostridium perfringens, and can be used for detecting the viable bacteria of the clostridium perfringens. According to the present invention, with the detection method, the false positive result caused by the existence of dead bacteria is avoided, the detection can be rapidly completed within 3 min, the voltage signal and the G value signal are mutually proved, the false positive or false negative of the single signal detection is effectively avoided, the detection limit is as low as 2.50 CFU / mL, and the excellent anti-interference ability in the complex food matrix such as chicken and milk is provided; the core element ITO glass electrode can be continuously and repeatedly used for 12 times, and the performance is not obviously attenuated.

This application belongs to the field of immunoassay technology, specifically relating to specific binding proteins of hepatitis B viruses (MHBs), nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides a specific binding protein of MHBs with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with large and small proteins, thus improving detection specificity and avoiding false positive results. The specific binding protein of MHBs in this application can bind to a chemiluminescent detection system, thereby achieving highly sensitive detection of MHB antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

This application belongs to the field of immunoassay technology, specifically relating to LHBs-specific binding proteins, nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides an LHBs-specific binding protein with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with medium and small proteins, thus improving detection specificity and avoiding false positive results. The LHBs-specific binding protein of this application can bind to chemiluminescent detection systems, thereby achieving highly sensitive detection of LHBs antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

The invention provides a multisystem disease analysis method based on gastrin plasma proteomics, which comprises the following steps of: A, analyzing a large number of adult individuals subjected to baseline evaluation by using queue research data of a biological sample library, and measuring a plurality of plasma proteins; b, analyzing a standardized protein expression (NPX) value of gastrin (GAST) by adopting a multivariable Cox proportional risk model, and correcting by using Bonferroni so as to reduce a false positive result; and C, exploring the correlation between the GAST-PRS and the disease phenotype by adopting full phenotype correlation analysis (PheWAS) based on polygene risk score (PRS), and further analyzing the genetic correlation between the GAST and the disease by using linkage imbalance score regression (LDSC). According to the method, the GAST can be redefined as a cross-system risk regulation factor, and the method is of great significance to layering of patients with shared pathway imbalance. The GAST has multi-system correlation with morbidity and mortality in the outcome of 168 diseases, and challenges the classical normal form of the gastrointestinal specific function of the GAST. These findings establish the location of GAST as a multi-system risk indicator.

The invention relates to the technical field of in-vitro diagnosis, in particular to a kit for detecting an allergen-specific IgE (Immunoglobulin E) antibody. The kit comprises an anti-interference agent used for being mixed with a to-be-detected sample, an immunolabelled allergen, a peroxidase compound capable of being combined with an immunolabel and catalyzing color development of a substrate, and the substrate capable of being catalyzed by peroxidase to develop color, the anti-interference agent is prepared from the following components in parts by weight: 3 to 6 parts of polystyrene microspheres, 12 to 18 parts of L-glucoside and 6 to 10 parts of casein. The kit provided by the invention can effectively reduce false positive and false positive results, so that the accuracy of the detection result is improved.

The invention relates to a method and a product for preventing false positive results in real-time fluorescent quantitative PCR detection of pathogens. The positive reference template provided by the invention is used for replacing a positive control template, so that a false positive result caused by the fact that a test sample is polluted by the positive control template in real-time fluorescent quantitative PCR detection of pathogens is prevented.

The invention describes a recombinant Mycobacterium strain such as M. smegmatis that is recombinantly converted to express the M. tb complex ESX protein expression system, e.g. M. tb complex ESX-1 protein expression system. The recombinant strain exports virulence effector proteins (such as EspA, EspB, EspC, EsxA or EsxB) similar to M. tb, when administered to a subject, and is therefore useful as a potential tuberculosis vaccine candidate. The recombinant strain is non-pathogenic and the vaccinated subject does not give a false positive result when tested with any standard tuberculosis diagnostic test e.g. CCT, as the recombinant strain does not sensitize the vaccinated host to M. tb antigens or protein derivate of M. bovis.

The application discloses a primer probe combination, a kit and application for detecting Nocardia, a mycobacterium tuberculosis complex and mycobacterium, and belongs to the technical field of genetic engineering. The technical problem to be solved is that there is a lack of a nucleic acid detection tool for Nocardia, the mycobacterium tuberculosis complex and mycobacterium in the prior art, which is high in sensitivity, high in specificity and simple in operation. The technical solution is characterized in that the primer probe combination comprises a primer probe for detecting Nocardia, a primer probe for detecting the mycobacterium tuberculosis complex, a primer probe for detecting mycobacterium and a primer probe for detecting an internal standard control. The primer probe combination can simultaneously screen Nocardia, the mycobacterium tuberculosis complex and mycobacterium, quickly and simply confirms pathogenic species, saves time, manpower and reagent cost, and has the advantages of high specificity, a low minimum detection limit and prevention of false negative or false positive results.

A tumor stroma imaging agent with a chemical structural formula (I):is provided, where R is hydrogen or fluorine. Compared with the prior art, the tumor stroma imaging agent exhibits significant affinity for fibroblast activation protein (FAP), high uptake for a malignant tumor with high FAP expression in a tumor stroma, and high sensitivity and specificity for the diagnosis of a malignant tumor, and is not prone to false positives. Therefore, the tumor stroma imaging agent can be effectively and safely used for the diagnosis and treatment of various malignant tumors with a prolonged half-life and an extended window period, which is conducive to clinical application.

The invention provides a near-infrared AIE fluorescent probe as well as a preparation method and application thereof. The fluorescent probe has obvious AIE property, aggregation-induced emission (AIE) effect and good light stability, can realize seven-day imaging of CAR-T cells, can target CAR-T cell mitochondria, cannot leak to other cells, and avoids false positive results. Meanwhile, the probe has good biocompatibility, does not influence CAR-T cells to secrete key cell factors IFN-gamma, and does not damage the killing function of the CAR-T cells on tumor cells. In a small animal living body level, the probe N-6 is used for tracing CD19 CAR-T cells in a Raji subcutaneous tumor model mouse, a result shows that a fluorescence signal can be continuously observed for 7 days, and the CAR-T cells are continuously enriched in tumor tissues and liver tissues, which indicates that the probe N-6 can monitor the dynamic distribution process of the CAR-T cells in vivo in real time.

The invention discloses a primer and a product for detecting and identifying plant lactobacillus, application and a method, and relates to the technical field of biological detection. The primers comprise the primers as shown in SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3. According to the invention, the specific primer is designed aiming at the plant lactobacillus, and the primer has high species specificity, can effectively identify the specific DNA sequence of the plant lactobacillus, and avoids cross reaction with other lactic acid bacteria, so that the probability of occurrence of false positive results is obviously reduced. In a complex sample, even if multiple other microorganism DNAs exist, the specific primer provided by the invention can still efficiently amplify the DNA fragment of a target strain, so that the detection sensitivity and accuracy are improved, and a trace amount of plant lactobacillus can be stably detected.

The application discloses a reagent card box and a nucleic acid extraction, purification and amplification integrated method. The reagent card box is provided with a center pool, a plurality of reagent cavities, a plurality of liquid storage pools, a plurality of ventilation channels and a plurality of first liquid channels. By controlling the air source to apply positive pressure through the ventilation hole, the liquid in the reagent cavity or the liquid storage pool sequentially passes through the corresponding first liquid channel, the rotating assembly and the membrane placement groove into the center pool. By controlling the air source to apply negative pressure through the ventilation hole, the liquid in the center pool sequentially passes through the membrane placement groove, the rotating assembly and the first liquid channel to return to the reagent cavity or the liquid storage pool, and the silica gel membrane is contacted twice in each step in the forward and reverse directions. The application can integrate a plurality of steps required for detection and analysis on a chip to complete sample pretreatment, manual sample addition, reagent mixing, optical detection and other complex operations, and can be used one time, has low cost and reduces false positive results and infection risks.

To eliminate and improve the risk of false positive results in sandwich ELISA.SOLUTION: A method for determining an analyte suspected of being present in a sample, the method comprising: (i) an anchor layer present on a solid support; (ii) a first binding agent capable of specifically binding to the analyte, wherein the first binding agent is anchored to the anchor layer and comprises at least one detectable label; (iii) a second binding agent capable of specifically binding to the analyte when bound to the first binding agent, wherein the second binding agent is immobilized on a solid support; and contacting under conditions and for a time allowing specific binding of the analyte suspected of being present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent, and detecting formation of a complex of the first binding agent, the analyte and the second binding agent, whereby the analyte is determined.SELECTED DRAWING: Figure 1

The invention discloses a biomarker for prognosis evaluation of extrahepatic cholangiocarcinoma, a prognosis risk evaluation system and application, and belongs to the technical field of bioinformatics. According to the present invention, the combination of miR-34c-5p, miR-100-5p, miR-193b-5p, miR-122-5p, miR-5588-5p and miR-122-3p is adopted as the biomarker, such that the accuracy of the extrahepatic cholangiocarcinoma differential diagnosis can be effectively improved, and the extrahepatic cholangiocarcinoma patients, the healthy population and the benign biliary tract disease patients can be distinguished with the high precision; the limitation that a traditional tumor marker, such as CA19-9, is easy to have a false positive result in benign biliary tract diseases is overcome; meanwhile, the change of the expression level of the biomarker combination can dynamically reflect the change of the postoperative tumor load, so that the accurate evaluation of the surgical curative effect is facilitated.

The application discloses a 21-hydroxylase deficiency screening kit and application thereof, relates to the blood analysis technical field, and a steroid hormone marker composition of 21-hydroxylase deficiency, wherein the nine markers comprise 17alpha-hydroxyprogesterone, androstenedione, 11-deoxycortisol, 21-deoxycortisol, cortisol, corticosterone, progesterone, dihydrotestosterone and 11-deoxycorticosterone; the kit can be used for screening 21-hydroxylase deficiency, 11beta-hydroxylase deficiency, 17alpha-hydroxylase deficiency and other types of diseases; the kit comprises detection components for detecting the hormones; compared with a traditional time-resolved fluorescence immunoassay method, the LC-MS / MS multi-index combined detection scheme adopted in the application can significantly reduce false positive results; and invalid recall, unnecessary family anxiety and medical burden caused by false positive results are greatly reduced.

Disclosed herein are methods for detecting a false positive initial sample result in a subject initially identified as having, or at risk for, cancer. Such methods can be performed on a sample obtained from the subject while undergoing a colonoscopy. Thus, methods can be useful for confirming or contradicting the initial identification that the high risk subject is at risk for cancer. Altogether, such methods are valuable for improving precision of a cancer test.

Provided are compositions and methods useful to the determination of whether a microbial contaminant is present in a biological therapeutic production process. Specifically, an artificial positive amplification control plasmid and unique quantitative PCR detection probe are provided, which enables the rapid and real-time detection of a false positive result.

The invention relates to the technical field of biomedicine, in particular to application of IFI27 protein as a marker for discriminating acute respiratory virus infection and non-virus infection. The detection marker provided by the invention can effectively eliminate false positive results in diagnosis, has the advantage of being capable of distinguishing bacterial infection or virus infection, and makes up for the defect that currently common inflammatory markers cannot prompt virus infection.

Blood sample optimization systems and methods are described that reduce or eliminate contaminates in collected blood samples, which in turn reduces or eliminates false positive readings in blood cultures or other testing of collected blood samples. A blood sample optimization system can include a blood sequestration device located between a patient needle and a sample needle. The blood sequestration device can include a sequestration chamber for sequestering an initial, potentially contaminated aliquot of blood, and may further include a sampling channel that bypasses the sequestration chamber to convey likely uncontaminated blood between the patient needle and the sample needle after the initial aliquot of blood is sequestered in the sequestration chamber.

The invention relates to the technical field of medical diagnosis, in particular to a multivariable electroencephalogram emotion decoding depression assessment method based on a time cluster strategy, and aims at solving the problems that when symptoms of a depression patient are detected at present, false positive results are extremely likely to occur due to the adoption of a multivariable analysis mode, and the depression assessment accuracy and reliability are poor. According to the method, electroencephalogram signals of a depression patient under an emotion recognition task are collected and preprocessed, then an individual decoding mode is calculated based on a time cluster strategy, time dynamic characteristics are extracted, and finally, cross validation is performed by adopting a leave-one-out method. The performance of the model in depressive symptom evaluation is evaluated by calculating the root-mean-square error and significance of the Bayesian model prediction score and the scale score, so that the problem of false positive in multivariate mode analysis is effectively avoided; time dynamic characteristics reflecting possible abnormal nerve states activated in emotion processing are stably extracted by the aid of electroencephalogram signals, depression evaluation is carried out on the basis of the characteristics, and prediction accuracy and reliability of depression evaluation are realized.

The invention discloses a combined marker for colorectal cancer detection and application of the combined marker. The combined marker is composed of an ALX4 gene, an SFRP2 gene, an SEPTIN9 gene, an SDC2 gene and a TFPI2 gene. Experiments prove that the ALX4 gene, the SFRP2 gene, the SEPTIN9 gene, the SDC2 gene and the TFPI2 gene are combined to diagnose the early colorectal cancer, the operation is simple, the consumed time is short, the sensitivity and the specificity are relatively high, the detection rate can be effectively improved, and false positive results are reduced. The method has an important application value.

The utility model belongs to the field of immune chromatography technology, disclose a kind of double control flow high sensitivity immune chromatography device, including bottom plate, sample pad, binding pad, dissolved breakaway isolation pad, chromatography pad and bibulous pad are sequentially arranged in sample flow direction on bottom plate, chromatography pad is sequentially provided with IgG detection line, IgM detection line and quality control line in sample flow direction, two hydrophobic isolation zones are provided on chromatography pad, one of which is located between IgG detection line and IgM detection line, another hydrophobic isolation zone is arranged between IgM detection line and quality control line, the utility model is provided with two hydrophobic isolation zones on chromatography pad, respectively between IgG detection line and IgM detection line, between IgM detection line and quality control line, using the strong hydrophobicity of polytetrafluoroethylene and the design of full coverage along the width direction, form physical barrier to block transverse flow, significantly reduce the generation of false negative, false positive result from the root, significantly improve the reliability of multiple detection.